Merck Fails To Win Zetia/Vytorin CV Risk Reduction Claim

Merck & Co. failed to convince the FDA to permit the firm to market its cholesterol-lowering medications Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) as therapies to reduce the risk of cardiovascular (CV) events – CV death, nonfatal heart attacks and strokes, hospitalization for unstable angina or the need for revascularization – in patients with coronary heart disease.